Objective: Noninvasive prenatal testing (NIPT) can assess chromosomes other than 13, 18, 21, X and Y. These rare autosomal trisomies (RATs) can adversely affect pregnancy outcome.
| INTRODUCTION
Noninvasive prenatal testing (NIPT) analyses cell-free DNA (cfDNA) in maternal plasma, which is a combination of DNA from maternal cells and from placental cytotrophoblast. 1 The technique of massively parallel sequencing (MPS) sequences and counts large numbers of unique, single locus DNA fragments and assigns them to the chromosome of origin. 2 It is possible to assess all chromosomes, but most platforms have only been validated for nonmosaic trisomies of chromosomes 13, 18, and 21 and for sex chromosome aneuploidies. The phenotypic variability of sex chromosome aneuploidy plus their lower positive predictive values and higher false-negative rates [3] [4] [5] has raised questions regarding their suitability for use in routine NIPT. 6 Similar arguments have been used in relation to microdeletion syndromes by organisations such as the American
College of Obstetrics and Gynaecology but could also apply to the analysis of trisomies involving the other 18 chromosomes not currently validated for NIPT. 7, 8 There is scant literature regarding rare autosomal trisomies (RATs) identified at NIPT. Three studies were identified that included cohorts of RATs with clinical outcome data. Early indications were that these cases generally had good outcomes, other than an increased risk of fetal growth restriction. 9 Three recent larger studies have identified higher rates of adverse outcome, including miscarriage and structural and genetic abnormalities along with neurodevelopmental delay. [10] [11] [12] Overall, the RAT numbers are small; there has been limited prospective investigation of the fetal genetics, and the accuracy of analysis can be questioned, particularly given the number of potential sources of error in NIPT analysis. 13 We present a prospective case series of RATs and their genetic and obstetric outcomes and review the available data regarding the clinical utility of screening and reporting of RATs at NIPT.
| METHODS
Prospective data were collected on consecutive blood samples collected from patients attending routine prenatal management through both private and public clinics from March 2015 to August 2017. Eligibility of patients was based on a singleton pregnancy, with no obvious abnormality, at a minimum of 10 weeks' gestation at sample collection with no other exclusion criteria. Samples were rejected if the gestation was under 10 weeks, there was insufficient sample volume, or more than 5 days had elapsed between sample collection and receipt in the laboratory. Repeat sample collection was sought in these scenarios. Detection of a fetal abnormality was seen as an indication for invasive testing and not for NIPT.
An ultrasound was performed, and then counselling was provided by a fetal medicine specialist or a genetic counsellor before the venipuncture. Screen accuracy for chromosomes 13, 18, 21, X and Y, were
given and assessment of the other chromosomes mentioned, but screen accuracy for these was not available. Counselling after an abnormal result was by a fetal medicine specialist or a geneticist.
Specimens were obtained the same day as a dating scan by routine venipuncture with 10-mL blood collected into a glass Streck tube and preserved as whole blood at room temperature for 1 to 5 days until DNA extraction. Samples were processed according to Illumina's documented protocol for the preparation of plasma for cfDNA extraction.
One-third of patients also had 3.5-mL blood collected into a serum tube concurrently for first trimester biochemical assessment of pregnancy-associated plasma protein-A (PAPP-A), free β human chorionic gonadotrophin, and placental growth factor (PlGF) for first trimester pre-eclampsia risk assessment. These samples were centrifuged and separated within 6 hours of blood collection, and serum was stored at −20°C until analysis.
Cell-free DNA was isolated and prepared using the QIAamp DNA What's already known about this topic?
• Noninvasive prenatal testing can find trisomies other than on chromosomes 13, 18, 21, X and Y.
• These trisomies are principally placental in origin and can be associated with miscarriage and growth restriction, but also with true fetal mosaicism.
What does this study add?
• The pregnancy outcome depends on which chromosome is affected.
• There appears to be an increased incidence of a fetal structural anomaly, despite a normal amniocentesis microarray result.
• Growth restriction correlates strongly with placental protein levels, especially pregnancy-associated plasma Tables 1 and 2 , with complete details of antenatal investigations and pregnancy outcome shown in the Table S1 .
Of the 28 RAT cases, six miscarried, half due to anomalies in chromosome 22 (all three trisomy, 22 cases). Two cases had true fetal mosaicism (TFM) confirmed on amniocentesis, of which one also had structural anomalies and the other had both trisomy and UPD 15 on amniocentesis but no structural anomalies seen on ultrasound. One case with mosaic trisomy 10 on CVS and structural abnormalities seen on ultrasound had a likely, but unproven, fetal mosaicism. Termination of pregnancy occurred in four cases (the two TFM cases, the trisomy 10 case, and one trisomy 7 case, which had structural abnormalities despite a normal amniocentesis). In all, there were six cases with structural abnormalities, three mentioned above, and another three cases with anomalies found later in pregnancy (below), and these were live born. One case had structural anomalies found, and despite counselling suggesting invasive Table 3 . Five pregnancies (31%) were delivered preterm, four due to fetal growth restriction and one due to pre-eclampsia. Available outcome data from the current study and other relevant RAT studies are detailed in Table 4 .
Chromosome coverage values ranged from 1.020 to 1.099 in the 28 RAT cases. The six cases that miscarried had a median CCV of 
| DISCUSSION
To the best of our knowledge, this is the third, but largest study of prospectively reported and managed RATs from cfDNA testing.
11,12
Over a 27-month period, there were 28 RATs identified from over 23 000 samples submitted to a single laboratory, most commonly involving chromosomes 7 and 16. There were moderately high rates of miscarriage, TFM, fetal structural abnormality, fetal growth restriction, and preterm delivery among these cases. Only nine of the 28 cases (32%) were appropriately grown, live born, and phenotypically normal.
Despite a normal microarray result on amniocentesis (15 cases), four (27%) were found to have structural anomalies. The numbers are small, but it is higher than expected rate of fetal anomalies in genetically normal pregnancies (2.9% congenital malformation rate 16 ) and suggests an effect of the RAT in some organ systems, which were not detected on microarray analysis at amniocentesis.
In all cases of fetal growth restriction where placental serology results were available, the PAPP-A levels were below the second per- While RATs are uncommon, they are not rare. They occur between one of 93 and one of 835 NIPT samples depending on the population tested, the sequencing platform, and the CCV cut-off used by the laboratory. [9] [10] [11] At one in 835, the rate in the current study was significantly less than found in the other four studies 9-12 (P < 0.05).
The a priori risk of the study population, the method of selecting a RAT using a cut-off of 1.02 for the CCV and the fact that all NIPT samples were taken only after a live fetus was confirmed on pretest ultrasound, may explain the lower incidence of RATs in our study. In studies where no ultrasound is performed, or there is a delay of days or weeks between the scan and the NIPT sample collection, there is a chance that the fetus has demised, which can on occasions be due to a RAT such as trisomy 22. Occasionally, a fetal abnormality was seen on ultrasound, which was then seen as an indication for invasive testing rather than an NIPT, further reducing the incidence of finding a RAT on NIPT, although one of our cases still had NIPT in an attempt to avoid an amniocentesis. As a comparison, from this study cohort, there was one case of trisomy 21 for each 125 samples and one case of XXY for each 974 samples. The single most common microdeletion syndrome involves 22q11.2, and a recent study identified one case for each 1818 NIPTs, which is 2.5 times less common than the RAT frequency in this study. 18 The most common five microdeletions, part of the microdeletion panel of the Panorama NIPT (Natera, San Carlos, California), have a collective incidence of one in 1000 NIPTs at birth. 19 In 2014, Lau et al published on whole-genome sequencing in 1982 women, finding six RATs (one in 330). All resulted in a normal live baby, but two pregnancies were affected by intrauterine growth restriction. 9 They concluded that pregnancy outcome in RAT cases was generally good, but required surveillance for growth restriction.
Three recent papers show poorer outcomes for pregnancies identified with a RAT on cfDNA testing. In a large retrospective study, RATs (one in 281). 10 The most common RATs in these cohorts were Total 28
Abbreviations: CPM, confined placental mosaicism; FGR, fetal growth restriction; FSA, fetal structural abnormality on ultrasound; LB, live birth; MC, miscarriage; NAD, no abnormality detected; POC, trisomy confirmed on products of conception; PN, Postnatal anomalies found; TOP, termination of pregnancy. The outcome of RAT cases appears to be related to which chromosome is involved. A particularly poor prognosis was seen for trisomy 22, with all three of our cases miscarrying and three of the five cases from the Pertile study miscarrying. 10 Trisomy 15 cases also had high miscarriage rates (13 of 14 in Pertile study), and the two cases in the current study resulted in miscarriage and termination secondary to TFM. 10 Conversely most, but not all, of the trisomy 7 cases, the most common RAT in the current study, had a good outcome. Trisomy 16 was often associated with growth restriction, but with close monitoring, they usually resulted in a live birth of a phenotypically normal baby.
The strengths of this study include the large number of NIPTs, the addition of placental biochemistry, and being prospective. was not performed in 13 cases where no abnormality was seen on prenatal invasive testing, where low-level maternal mosaicism may have been the cause of the NIPT finding. As follow-up was only collected for the RAT cases, we are unable to assess the sensitivity for NIPT to detect a RAT.
| CONCLUSION
Rare autosomal trisomies are not rare and until recently were hidden from clinicians. Rare autosomal trisomies are often associated with poor obstetric outcome, which differs depending on the particular chromosome affected. A low PAPP-A level in the presence of a RAT and normal karyotype indicates a higher chance of growth restriction, which is likely to be due to confined placental mosaicism. Even after a normal amniocentesis, the possibility of a fetus with structural anomalies or a syndrome that may be related to the trisomy found at NIPT still exists. This study provides further evidence that laboratories who can identify RATs should report them to the referring clinician. 
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